HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation.

Yening Feng,Cristobal Tomas Sanhueza Condell,Christopher L. Hallemeier,Shanda H. Blackmon,Joleen M Hubbard,Thorvardur R. Halfdanarson,Timothy J. Hobday,Stephen D. Cassivi,Robert Shen,Michelle A. Neben Wittich,Francis C. Nichols,Kenneth W. Merrell,Ellen W. Blanco,Robert R. McWilliams,Steven R. Alberts,Henry C. Pitot,Aminah Jatoi,Michael G. Haddock,Dennis A. Wigle,Harry H. Yoon

HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation.

2021

239Background: After trastuzumab (T) approval for advanced HER2-positive E/GEJ-AC, HER2 testing has increased in patients (pts) with resectable disease. Neoadjuvant carboplatin/paclitaxel chemoradi...

Keywords:

Internal medicine
Oncology
Carboplatin
Carboplatin/paclitaxel
in patient
Trastuzumab
Paclitaxel
resectable disease
Gastroesophageal Junction Adenocarcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations